default author photo

Juan Tao

Huazhong University of Science and Technology - Union Hospital

Wuhan

China

SCHOLARLY PAPERS

4

DOWNLOADS

318

TOTAL CITATIONS

2

Scholarly Papers (4)

1.

Prevalence and Patient-Reported Outcomes of Noncommunicable Skin Diseases Among Adolescents: A Population-Based Study in China

Number of pages: 27 Posted: 20 Dec 2019
Central South University - Department of Social Medicine and Health Management, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Huazhong University of Science and Technology - Union Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Inner Mongolia Medical University, Xiamen University, Xiamen University and Central South University - Department of Dermatology
Downloads 125 (576,708)
Citation 1

Abstract:

Loading...

noncommunicable skin diseases; patient-reported outcomes; health-related quality of life; adolescent health

2.

A Panoramic View of Clinical Features of Lupus Erythematosus, a Cross-Sectional Multicenter Study from China

Number of pages: 39 Posted: 04 Apr 2022
Central South University - Key Laboratory of Diabetes Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Key Laboratory of Diabetes Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Second Xiangya Hospital, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Second Xiangya Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Second Xiangya Hospital, affiliation not provided to SSRN, Central South University - Second Xiangya Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Key Laboratory of Diabetes Immunology, affiliation not provided to SSRN, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Key Laboratory of Diabetes Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Key Laboratory of Diabetes Immunology, affiliation not provided to SSRN, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Key Laboratory of Diabetes Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Second Xiangya Hospital, Central South University - Key Laboratory of Diabetes Immunology, Central South University - Key Laboratory of Diabetes Immunology, Central South University, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Second Xiangya Hospital, Central South University - Second Xiangya Hospital, Central South University - Second Xiangya Hospital, Central South University - Second Xiangya Hospital, Central South University - Department of Rheumatology, Central South University - Department of Rheumatology, Anhui Medical University, Government of the People's Republic of China - Department of Dermatology, Guangxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Nanjing University - Department of Rheumatology and Immunology, Central South University - Key Laboratory of Diabetes Immunology, Zhejiang University, affiliation not provided to SSRN, Kunming Medical University, affiliation not provided to SSRN, Harbin Medical University, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Second Xiangya Hospital, Central South University - Second Xiangya Hospital, affiliation not provided to SSRN, Shandong University - Qilu Hospital, University of South China, University of South China, Government of the People's Republic of China - Beijing Hospital, Chongqing Hospital of Traditional Chinese Medicine, Huazhong University of Science and Technology - Union Hospital, Zhengzhou University - First Affiliated Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, Chongqing Medical University, Central South University - Key Laboratory of Diabetes Immunology, Heilongjiang Provincial Hospital, Government of the People's Republic of China - Army Medical University, Central South University - Second Xiangya Hospital, Central South University - Key Laboratory of Diabetes Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Central South University - Second Xiangya Hospital, affiliation not provided to SSRN, Central South University - Key Laboratory of Diabetes Immunology and Central South University - Hunan Key Laboratory of Medical Epigenomics
Downloads 83 (790,029)

Abstract:

Loading...

SLE, CLE, skin lesion, mucosal damage, clinical features

3.

RJT-101, a Novel Camptothecin Derivative, Is Highly Effective in the Treatment of Melanoma Through DNA Damage by Targeting Topoisomerase 1

Number of pages: 44 Posted: 27 May 2019
Central South University - Department of Dermatology, Southwest Medical University, Chifeng Saliont Pharmaceuticals Co. Ltd., Central South University - Department of Dermatology, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Huazhong University of Science and Technology - Union Hospital, Central South University - Third Xiangya Hospital, Central South University - Department of Dermatology and Central South University - Department of Dermatology
Downloads 59 (970,490)

Abstract:

Loading...

Melanoma, RJT-101, Topoisomerase I, DNA damage

4.

A Randomized, Double-Blind Phase III Study to Demonstrate the Clinical Similarity of Biosimilar SCT630 to Reference Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis

Number of pages: 27 Posted: 01 Jun 2022
Government of the People's Republic of China - Xijing Hospital, Government of the People's Republic of China - Xijing Hospital, Shandong First Medical University - Shandong Provincial Hospital, Tongji University - Shanghai Skin Disease Hospital, Jiangsu University - Affiliated Hospital, Tsinghua University - Beijing Tsinghua Changgung Hospital, Naval Medical University - Changhai Hospital, Shanxi Medical University - First Hospital, People's Hospital of Hangzhou Medical College - Zhejiang Provincial People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Shandong University - Qilu Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Fudan University - Huashan Hospital, Sichuan University - West China Hospital, Southwest University - Southwest Hospital, Central South University - Second Xiangya Hospital, Government of the People's Republic of China - Air Force Medical Center, Central South University - Department of Dermatology, Kunming Medical University - Second Affiliated Hospital, Harbin Medical University - Second Affiliated Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Huazhong University of Science and Technology - Union Hospital, Sinocelltech Ltd., Sinocelltech Ltd. and Sinocelltech Ltd.
Downloads 51 (1,074,648)
Citation 1

Abstract:

Loading...

adalimumab, SCT630, plaque psoriasis